Min H. Hong

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 144 publications

Corrigendum to "A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma" [Oral Oncol. 170 (2025) 107745].

Corrigendum to "A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma" [Oral Oncol. 170 (2025) 107745].

Journal: Oral oncology
Published: September 04, 2026

Corrigendum to "A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma" [Oral Oncol. 170 (2025) 107745].

Corrigendum to "A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma" [Oral Oncol. 170 (2025) 107745].

Journal: Oral oncology
Published: June 19, 2026

Central Nervous System Activity of Lazertinib in EGFR-Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG-LU20-15 and LU21-01.

Central Nervous System Activity of Lazertinib in EGFR-Mutated NSCLC With Prior EGFR TKI Exposure: A Pooled Analysis of KCSG-LU20-15 and LU21-01.

Journal: Thoracic cancer
Published: June 03, 2026

High-dimensional immune profiling of peripheral blood identifies immune correlates of anti-PD-1/PD-L1 resistance in oncogenic driver mutation-positive NSCLC.

High-dimensional immune profiling of peripheral blood identifies immune correlates of anti-PD-1/PD-L1 resistance in oncogenic driver mutation-positive NSCLC.

Journal: Frontiers in immunology
Published: March 13, 2026

Corrigendum to 'Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer': [ESMO Open. Volume 11, Issue 2, February 2026, 106057].

Corrigendum to 'Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer': [ESMO Open. Volume 11, Issue 2, February 2026, 106057].

Journal: ESMO open
Published: March 11, 2026

A Randomized, Nivolumab-controlled, Phase 2 and Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus.

A Randomized, Nivolumab-controlled, Phase 2 and Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 09, 2026

EpCAM+ Extracellular Vesicle PD-L1 Dynamics as a Predictive Biomarker of Immune Checkpoint Blockade Response.

EpCAM+ Extracellular Vesicle PD-L1 Dynamics as a Predictive Biomarker of Immune Checkpoint Blockade Response.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: January 14, 2026

A Phase II Study of Stereotactic Ablative Radiotherapy plus Atezolizumab plus Tiragolumab in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer.

A Phase II Study of Stereotactic Ablative Radiotherapy plus Atezolizumab plus Tiragolumab in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 01, 2026

Atezolizumab and bevacizumab plus chemotherapy versus chemotherapy in non-small cell lung cancer after tyrosine kinase inhibitor failure.

Atezolizumab and bevacizumab plus chemotherapy versus chemotherapy in non-small cell lung cancer after tyrosine kinase inhibitor failure.

Journal: Therapeutic advances in medical oncology
Published: December 04, 2025

JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC.

JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 02, 2025

Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer.

Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer.

Journal: ESMO open
Published: October 01, 2025

BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations.

BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR Mutations.

Journal: Molecular cancer therapeutics
Published: September 05, 2025
Showing 1-12 of 144

Last Updated: 09/26/2026